Rarely has progress in treatment of leukemia been as dramatic and convincing as with the BCR-ABL tyrosine kinase inhibitor imatinib.
The dilemma comes with the progress and is two-fold: interferon a, in a substantial minority of patients prolongs survival.
3,4 Also, long-term survival and probably cure can be achieved with allogeneic stem cell transplantation in the majority of CML patients who have a donor and can tolerate the procedure, although mortality and morbidity associated with allografting may be considerable. [5] [6] [7] Sensitive PCR techniques confirm the absence of minimal residual disease in most transplanted patients, thereby supporting the notion that these patients are cured of CML. 8 In contrast, because of the limited experience, no information on long-term survival with imatinib is available yet. The observation of imatinib resistance even in chronic phase 9 and of residual disease in complete cytogenetic responders, casts doubt on the life prolonging potential of imatinib monotherapy in every CML patient.
The question that now arises for many patients and their doctors is how to make use of the therapeutic progress offered by imatinib, while retaining the life prolonging or curative options offered by interferon a and by stem cell transplantation.
Helpful in this situation may be the consideration of the risk profile at diagnosis as assessed by the new prognostic score 3 and of the transplantation risk as determined by the EBMT score.
6 A low-risk patient for instance, who responds to interferon a has a probability to survive 10 years or longer of about 40%. 3 If this patient achieves a major or complete cytogenetic response, his 10-year-survival probability increases to 80-90%. Intermediaterisk patients as a group have a somewhat inferior prognosis, but this group still comprises patients with good long-term survival probabilities (about 20% at 10 years). An update of current response and survival data after imatinib, interferon a and stem cell transplantation is presented in Table 1 . 10 One therapeutic option would therefore be to start on interferon a and turn to imatinib only if response and tolerability are not (or not any more) satisfactory. The risk of disease progression during the trial with interferon a would be more than outweighed by the higher chances of long-term survival, if a response to interferon a is achieved. This option is supported by the experience that imatinib is highly active also after interferon a failure, 13 and by the observation that interferon a and imatinib may complement each other because of different mechanisms of action by which the two drugs may achieve remissions. 14 A second option would be to try to retain optimum chances for a potentially curative early stem cell transplantation by proceeding to transplantation early, since it has been well documented that transplantation is the more successful the earlier, in the course of the disease, it is carried out.
5 There are two scenarios in which an early transplantation should be considered also in the imatinib era: high-risk patients do not profit from interferon a treatment and it is unclear whether imatinib will improve their prognoses. If transplantation risk is acceptable, this patient group should receive early transplantation. A second group that may qualify for early transplantation are patients with very low transplantation risk such as very young patients who have well-matched donors.
In view of the transplantation risks, however, the majority of patients will prefer a less risky treatment option that offers a reasonable chance of prolongation of life at acceptable toxicity. Already interferon a offered such an option when it became clear that a substantial minority of interferon a-treated patients had excellent survival prospects. An even more convincing option is now imatinib because of its excellent response rates and low toxicity.
For this group of patients essentially two alternatives are available: they either start on imatinib, continue with imatinib as long as reasonable and proceed to allografting or alternative therapy only after imatinib failure. Alternatively, these patients may start on interferon a (combined with hydroxyurea as needed 15 ) to retain their chances of being an interferon a responder with excellent long-term prognosis and proceed to imatinib only after interferon a is not, or not any more, satisfactory (interferon a failure).
These therapeutic options are illustrated by the treatment algorithm in Figure 1 . Although algorithms have their drawbacks because of potential oversimplification, we suggest that the enclosed algorithm may be helpful in this situation. It is likely that the options will change with increasing experience with imatinib and the development of new additional treatment modalities.
At present several lines of treatment research try to improve drug treatment of CML. One line is to increase the imatinib dosage to 600 or 800 mg/day on the basis of favourable experience with higher dosages in advanced phase disease. interferons. 17, 18 A third line is the combination of imatinib with other effective CML drugs such as interferon a and arabinosyl cytosine (araC). Phase I studies have demonstrated the feasibility of the combination of imatinib with interferon a, araC and most conventional cytostatic agents tested thus far. 19 Several randomized treatment optimization trials comparing imatinib with imatinib in combination with interferon a or araC are underway, one of which, CML-study IV of the German CML Study Group, has been started in July 2002. 20 If indeed a life prolonging effect of imatinib can be shown in due time, this would alter the management of CML profoundly. Until then, however, we are confronted to live with the current dilemma -and have to make the best out of it. 
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Treatment algorithm for CML in chronic phase.
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